|Mr. Richard Marsden||CEO, MD & Exec. Director||289k||N/A||1968|
|Mr. John Ward||Fin. Director, Company Sec. & Exec. Director||226k||N/A||1962|
|Dr. Phillip David Monk||Chairman of Scientific Advisory Board, Chief Scientific Officer & Exec. Director||208k||N/A||1969|
|Prof. Donna Davies||Co-Founder & Member of Scientific Advisory Board||N/A||N/A||N/A|
|Prof. Ratko Djukanovic||Co-Founder & Member of Scientific Advisory Board||N/A||N/A||N/A|
Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-Ã), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-Ã that is in Phase-II clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold and flu; and LOXL2 inhibitor, which has completed Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver diseases. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Synairgen plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.